Cyclerion Therapeutics, Inc. Board of Directors

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Dr. Todd Milne Ph.D.

Dr. Todd Milne Ph.D.

Senior Vice President of External Innovation

Ms. Jessica Rennekamp

Ms. Jessica Rennekamp

Associate Director of Corporate Communications

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.